Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
about
Pediatric response to second-line antiretroviral therapy in South AfricaDarunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020APRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to <12 Years.Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients.Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Darunavir: an effective protease inhibitor for HIV-infected patients.Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children.Early outcomes of darunavir- and/or raltegravir-based antiretroviral therapy in children with multidrug-resistant HIV at a pediatric center in Botswana.Darunavir: a review of its use in the management of HIV-1 infection.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Darunavir: A Review in Pediatric HIV-1 Infection.Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
P2860
Q34490216-25B89020-951F-405C-898B-530D51F810D2Q34638302-8CD768FB-E582-4A66-A8EC-4D6CB6CAB042Q35163596-9B84C234-2192-4B13-8CF8-BAC70FC285A3Q35722000-DCDEE017-054D-48B2-AB5D-B41BA35B6B96Q35792853-E0A989EF-7B59-49E7-99A6-44F3E6B410E5Q35965800-00E1F40D-2208-4F1E-BEDD-7BF6D43FF6DAQ35979557-D2448683-290C-4A89-AB67-624DB12E0A12Q36157266-61F2AEE1-9520-48C4-80D3-104C9B2EB7FFQ37473017-7DC1F63B-20DA-4F21-92C2-1511DB0DF2A8Q37589028-C1DC4AB2-072B-43A0-AAEA-3E949432EA22Q37816391-EF27DD94-5840-49BB-A781-C71A568CDDA0Q37835819-3689BEA0-FD1E-463C-982B-FB05B6D66582Q37892551-E70AE3D4-2838-4EB6-A646-CD23DE584374Q37925813-5025843C-3709-4277-9FCD-884CA357CC34Q38040150-6CF97C12-BFA8-4153-B88A-1DAC90B10DC5Q38073734-D393D401-8D29-4572-ACFD-2AB1F8CC5A2EQ38171346-8BD7C3FE-2987-4416-863E-202CB742FC80Q38222092-1CC19057-109B-4D39-A46E-C43AA06A333BQ38577433-9AD0B278-F41E-4148-B285-2924DF594637Q39831448-DE153873-7ACA-489C-B2BA-3702D2E0896EQ39901450-67FF51B1-D8E1-4830-AA84-DDD21D48D9C1Q42199714-6A7FD827-8C3D-405B-BC22-8EA64F8EFFD2Q42696471-1F6CB657-08DD-446C-BCAF-7380B194512EQ47602387-5268FF90-959F-4545-B1E4-4B877EA55FFB
P2860
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacokinetics, safety and e ...... nced children and adolescents.
@en
Pharmacokinetics, safety and e ...... nced children and adolescents.
@nl
type
label
Pharmacokinetics, safety and e ...... nced children and adolescents.
@en
Pharmacokinetics, safety and e ...... nced children and adolescents.
@nl
prefLabel
Pharmacokinetics, safety and e ...... nced children and adolescents.
@en
Pharmacokinetics, safety and e ...... nced children and adolescents.
@nl
P2093
P1433
P1476
Pharmacokinetics, safety and e ...... nced children and adolescents.
@en
P2093
Ben van Baelen
Claudia Fortuny
Inge Dierynck
Patricia Flynn
Pedro Cahn
Rosa Bologna
Sabrina Spinosa-Guzman
Sorin Rugina
Stéphane Blanche
P304
P356
10.1097/QAD.0B013E328330ABAA
P407
P577
2009-09-01T00:00:00Z